August 25, 2008
Phase 1b/2a Program Commences for RVX-208
CALGARY, Aug. 25 /PRNewswire-FirstCall/ -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that the Phase 1b/2a program for the study of RVX-208 in subjects with normal lipids and those with low high-density lipoprotein (HDL) cholesterol has proceeded according to plan.
"We are very excited about moving forward into this important 28-day study with RVX-208. Our previous clinical study demonstrated that RVX-208 was safe, tolerable and had favorable pharmacokinetics," stated Dr. Allan Gordon, Senior Vice President Clinical Development of Resverlogix. "This trial will continue to examine safety and tolerance as well it is a proof of principle study for ApoA-I production and HDL functionality. Approximately half of the subjects will have low levels of HDL cholesterol, a condition associated with significant increased risk of cardiovascular disease," added Dr. Gordon."The ensuing Phase 1b/2a study comprises several novel facets to expedite the clinical process for RVX-208 and its eventual registration as a drug," stated Donald J. McCaffrey, President and CEO of Resverlogix. McCaffrey further confirmed, "Along with the required regulatory provisions that must be addressed such as safety, tolerance and pharmacokinetics, the study also will measure key reverse cholesterol transport markers which RVX-208 impacts. These are exclusive favorable features that make this drug unique among its competitors."
RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-I production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com/.
This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.
CONTACT: Theresa Kennedy, VP, Corporate Communications, ResverlogixCorp., Phone: (604) 538-7072, Email: Theresa@resverlogix.com; SarahZapotichny, Manager, Investor Relations, Resverlogix Corp., Phone: (403)254-9252, Email: Sarah@resverlogix.com; Website: http://www.resverlogix.com/